{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T18:57:51Z","timestamp":1795201071207,"version":"4.10.3"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["DL2022194002L"],"award-info":[{"award-number":["DL2022194002L"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013262","name":"State Key Laboratory of Respiratory Disease","doi-asserted-by":"publisher","award":["2060204"],"award-info":[{"award-number":["2060204"]}],"id":[{"id":"10.13039\/100013262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences &amp; Peking Union Medical College","doi-asserted-by":"publisher","award":["CIFMS 2023-I2M-2-001"],"award-info":[{"award-number":["CIFMS 2023-I2M-2-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["HLCMHPP2023130"],"award-info":[{"award-number":["HLCMHPP2023130"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"National Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["ZYYCXTD-C-202205"],"award-info":[{"award-number":["ZYYCXTD-C-202205"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijbiomac.2026.152566","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:57:44Z","timestamp":1778889464000},"page":"152566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative study on PD-L1\/ALK dual-targeted biomimetic exosomes by two preparation approaches in pancreatic cancer"],"prefix":"10.1016","volume":"367","author":[{"given":"Chenyu","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaoxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152566_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0010","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41598-025-86664-x","article-title":"Clinical significance of PCT, CRP, IL-6, NLR, and TyG Index in early diagnosis and severity assessment of acute pancreatitis: a retrospective analysis","volume":"15","author":"Xinyu","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152566_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36922\/cp.3793","article-title":"MXene-montmorillonite nanocomposites-based scaffold sensors for early pancreatic cancer diagnosis","volume":"6","author":"Sadiq","year":"2024","journal-title":"Cancer Plus"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.152566_bb0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.152566_bb0025","article-title":"PD-L1 immune checkpoint targeted photoactivable liposomes (iTPALs) prime the stroma of pancreatic tumors and promote self-delivery","volume":"13","author":"Bhandari","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.152566_bb0030","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 Randomized Clinical Trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.152566_bb0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-025-01517-8","article-title":"Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis","volume":"43","author":"Pan","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0040","first-page":"20","article-title":"ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies","volume":"7","author":"Poei","year":"2024","journal-title":"Cancer Drug Resist."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152566_bb0045","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1094598","article-title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients","volume":"5","author":"Hong","year":"2016","journal-title":"Oncoimmunology"},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.152566_bb0050","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152566_bb0055","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3","volume":"5","author":"Koh","year":"2016","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152566_bb0060","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/cas.14397","article-title":"In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer","volume":"111","author":"Du","year":"2020","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152566_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3892\/or.2021.7979","article-title":"Anaplastic lymphoma kinase inhibitor NVP-TAE684 suppresses the proliferation of human pancreatic adenocarcinoma cells","volume":"45","author":"Duong","year":"2021","journal-title":"Oncol. Rep."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.152566_bb0070","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.18632\/oncotarget.2363","article-title":"Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer","volume":"5","author":"Yan","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116827","article-title":"Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers","volume":"279","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152566_bb0080","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152566_bb0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10637-019-00802-7","article-title":"Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma","volume":"38","author":"Li","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"747","key":"10.1016\/j.ijbiomac.2026.152566_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abj5879","article-title":"IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells","volume":"15","author":"Remsing Rix","year":"2022","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12943-016-0576-5","article-title":"IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.152566_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000430852","article-title":"Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data","volume":"38","author":"Toyokawa","year":"2015","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0105","doi-asserted-by":"crossref","first-page":"G109","DOI":"10.1152\/ajpgi.00130.2019","article-title":"Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer","volume":"318","author":"Jamshed","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.152566_bb0110","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ijc.33754","article-title":"A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors","volume":"149","author":"Fountzilas","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0115","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2195517","article-title":"\u201cStapling\u201d scFv for multispecific biotherapeutics of superior properties","volume":"15","author":"Boucher","year":"2023","journal-title":"MAbs"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.152566_bb0125","first-page":"5368","article-title":"Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy","volume":"13","author":"Huang","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152566_bb0130","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1039\/D4NR03224A","article-title":"Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer","volume":"17","author":"Vozgirdaite","year":"2025","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.152566_bb0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1166\/jbn.2021.3043","article-title":"Anti-human epidermal growth factor receptor 2 single-chain Fv fragment-decorated DM1 nanoparticles for specific targeting of human epidermal growth factor receptor 2-positive breast tumor cells","volume":"17","author":"Ni","year":"2021","journal-title":"J. Biomed. Nanotechnol."},{"issue":"Pt 1","key":"10.1016\/j.ijbiomac.2026.152566_bb0140","article-title":"An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia","volume":"254","author":"Mohamed","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.152566_bb0145","doi-asserted-by":"crossref","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","article-title":"Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152566_bb0150","first-page":"530","article-title":"Oxaliplatin-loaded chitosan nanoparticles decorated with cetuximab single-chain variable fragment for human colorectal cancer treatment","volume":"26","author":"Falahzadeh","year":"2025","journal-title":"Cell J."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12951-023-02126-4","article-title":"scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells","volume":"21","author":"Silveira","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0160","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.actbio.2022.11.043","article-title":"Functionalized biomimetic nanoparticles combining programmed death-1\/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy","volume":"157","author":"Xiao","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216220","article-title":"Advances in lipid-based carriers for cancer therapeutics: liposomes, exosomes and hybrid exosomes","volume":"565","author":"Moholkar","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0170","article-title":"Research progress in membrane fusion-based hybrid exosomes for drug delivery systems","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"29","key":"10.1016\/j.ijbiomac.2026.152566_bb0175","doi-asserted-by":"crossref","first-page":"18475","DOI":"10.1039\/D2RA02351B","article-title":"Exosome-based drug delivery systems and their therapeutic applications","volume":"12","author":"Lee","year":"2022","journal-title":"RSC Adv."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.152566_bb0180","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1039\/D4NA00501E","article-title":"A comprehensive review of challenges and advances in exosome-based drug delivery systems","volume":"6","author":"Palakurthi","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0185","article-title":"Engineering hybrid exosomes by membrane fusion with liposomes","volume":"6","author":"Sato","year":"2016","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.152566_bb0190","article-title":"Thermosensitive exosome-liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer","volume":"7","author":"Lv","year":"2020","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152566_bb0195","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1021\/acsnano.4c11024","article-title":"Photosensitive hybrid \u03b3\u03b4-T exosomes for targeted cancer photoimmunotherapy","volume":"19","author":"Gao","year":"2025","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152566_bb0200","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/ijms25073645","article-title":"Enhanced therapeutic potential of hybrid exosomes loaded with paclitaxel for cancer therapy","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118802","article-title":"Engineered extracellular vesicles with synthetic lipids via membrane fusion to establish efficient gene delivery","volume":"573","author":"Jhan","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.152566_bb0210","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1021\/acsabm.4c00658","article-title":"Hybrid nanoparticles of extracellular vesicles and gemcitabine prodrug-loaded liposomes with enhanced targeting ability for effective PDAC treatment","volume":"7","author":"Kim","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120761","article-title":"Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis","volume":"271","author":"Sun","year":"2021","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.152566_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700611","article-title":"Exosome-liposome hybrid nanoparticles deliver CRISPR\/Cas9 system in MSCs","volume":"5","author":"Lin","year":"2018","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315168","article-title":"Mesenchymal stem cell-derived exosome and liposome hybrids as transfection nanocarriers of Cas9-GFP plasmid to HEK293T cells","volume":"20","author":"Gharehchelou","year":"2025","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152566_bb0230","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.langmuir.4c04297","article-title":"Acidic conditions promote clustering of cancer cell derived extracellular vesicles and enhance their fusion with synthetic liposomes","volume":"41","author":"Fisher","year":"2025","journal-title":"Langmuir"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.152566_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050667","article-title":"Swelling, rupture and endosomal escape of biological nanoparticles per se and those fused with liposomes in acidic environment","volume":"16","author":"Ponomareva","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.152566_bb0240","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0245","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/21691401.2023.2264358","article-title":"Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy","volume":"51","author":"Zhou","year":"2023","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s13238-017-0412-8","article-title":"Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab","volume":"9","author":"Tan","year":"2018","journal-title":"Protein Cell"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.152566_bb0255","doi-asserted-by":"crossref","first-page":"28193","DOI":"10.1021\/acsami.4c04604","article-title":"Targeted ferroptosis-immunotherapy synergy: enhanced antiglioma efficacy with hybrid nanovesicles comprising NK cell-derived exosomes and RSL3-loaded liposomes","volume":"16","author":"Hao","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0260","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.actbio.2019.05.054","article-title":"Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery","volume":"94","author":"Rayamajhi","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120964","article-title":"Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy","volume":"275","author":"Cheng","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.152566_bb0270","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/0008-5472.CAN-12-2071","article-title":"Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors","volume":"73","author":"Huo","year":"2013","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152566_bb0275","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3923\/ijp.2024.1281.1291","article-title":"Alendronate sodium combined glatiramer acetate nanocomplex suppresses pancreatic cancer cell growth","volume":"20","author":"Abdel-Naim","year":"2024","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1482087","article-title":"Bone marrow mesenchymal stem cell-derived exosomes improve cancer drug delivery in human cell lines and a mouse osteosarcoma model","volume":"14","author":"Cai","year":"2024","journal-title":"Front. Oncol."},{"issue":"49","key":"10.1016\/j.ijbiomac.2026.152566_bb0285","doi-asserted-by":"crossref","first-page":"34211","DOI":"10.1074\/jbc.M109.041152","article-title":"Microenvironmental pH is a key factor for exosome traffic in tumor cells","volume":"284","author":"Parolini","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.882363","article-title":"Understanding the role and impact of poly (ethylene glycol) (PEG) on nanoparticle formulation: implications for COVID-19 vaccines","volume":"10","author":"Padin-Gonzalez","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"41","key":"10.1016\/j.ijbiomac.2026.152566_bb0295","article-title":"Biointerface-engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment","volume":"36","author":"Zhen","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2430302","article-title":"Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.152566_bb0305","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1021\/acsnano.8b02053","article-title":"Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems","volume":"12","author":"Piffoux","year":"2018","journal-title":"ACS Nano"},{"issue":"37","key":"10.1016\/j.ijbiomac.2026.152566_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202503807","article-title":"Droplet squeeze microfluidic platform for generating extracellular vesicle hybrids for drug delivery","volume":"21","author":"Chintapula","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ijbiomac.2026.152566_bb0315","article-title":"Microfluidic generation of exosome-mimetic nanoparticles for scalable production and enhanced therapeutic efficacy","author":"Kim","year":"2025","journal-title":"Small"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026024931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026024931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:16:24Z","timestamp":1783145784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026024931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"alternative-id":["S0141813026024931"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.152566","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study on PD-L1\/ALK dual-targeted biomimetic exosomes by two preparation approaches in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.152566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152566"}}